Wave Life Sciences (WVE) Other Non-Current Assets (2014 - 2026)
Wave Life Sciences' (WVE) quarterly Other Non-Current Assets came in at $3.8 million in Q2 2026, up 0.82% YoY from $3.8 million in Q2 2025, and little changed on a QoQ basis from $3.8 million in Q1 2026.
Analysis
Wave Life Sciences (WVE) Other Non-Current Assets (2014 - 2026) Analysis & Trends
Wave Life Sciences (WVE) has 12 years of Other Non-Current Assets data on file, last reported at $3.8 million in Q2 2026.
- Quarterly Other Non-Current Assets rose 0.82% year-over-year to $3.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.8 million (up 0.82% YoY) and the FY2025 annual result came in at $3.8 million, changed 0.16% from the prior year.
- Other Non-Current Assets held at $3.8 million in Q2 2026, from $3.8 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $4.7 million in Q1 2023 to a low of $3.7 million in Q1 2022.
- A 5-year average of $3.8 million and a median of $3.7 million in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets advanced 27.64% — and 2024, when it dropped 20.28%.
- Tracing WVE's Other Non-Current Assets over 5 years: stood at $3.7 million in 2022, then changed by 0.0% to $3.7 million in 2023, then grew by 2.7% to $3.8 million in 2024, then increased by 0.16% to $3.8 million in 2025, then gained by 0.24% to $3.8 million in 2026.
- The last three Other Non-Current Assets figures came in at $3.8 million (Q2 2026), $3.8 million (Q1 2026), and $3.8 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Wave Life Sciences | 994.54 Mn | 626.53 Mn | - | 3.82 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.82 Mn |
| Mar 31, 2026 | 3.82 Mn |
| Dec 31, 2025 | 3.81 Mn |
| Sep 30, 2025 | 3.80 Mn |
| Jun 30, 2025 | 3.78 Mn |
| Mar 31, 2025 | 3.77 Mn |
| Dec 31, 2024 | 3.80 Mn |
| Sep 30, 2024 | 3.75 Mn |
| Jun 30, 2024 | 3.73 Mn |
| Mar 31, 2024 | 3.72 Mn |
| Dec 31, 2023 | 3.70 Mn |
| Sep 30, 2023 | 3.68 Mn |
| Jun 30, 2023 | 3.67 Mn |
| Mar 31, 2023 | 4.66 Mn |
| Dec 31, 2022 | 3.70 Mn |
| Sep 30, 2022 | 3.65 Mn |
| Jun 30, 2022 | 3.65 Mn |
| Mar 31, 2022 | 3.65 Mn |
| Dec 31, 2021 | 3.70 Mn |
| Sep 30, 2021 | 3.65 Mn |